Nomura Y, Tashiro H, Shinozuka K
Cancer. 1985 Feb 1;55(3):546-51. doi: 10.1002/1097-0142(19850201)55:3<546::aid-cncr2820550313>3.0.co;2-v.
In several sequences during the progression of cancer, the authors assayed estrogen receptors(ER) in 940 breast cancers and progesterone receptors(PgR) in 773 cancers. The percentages of ER+ and PgR+ cancers diminished according to the progression of malignancy. Sequential assays of ER and PgR were carried out in primary tumors and in the metastatic tumors at the first recurrence in 42 patients. During the disease-free interval, 10 (37%) of 27 ER+ tumors changed to ER- and all 15 ER- tumors remained negative. The hormone receptors were assayed before the treatments and after the tumor relapsed following regression or after the progression of cancer. The change of ER and PgR in 99 patients with advanced breast cancer were studied according to the type of systemic treatments. Through endocrine therapy, marked changes from ER+ to ER-, were noted (by antiestrogens, 47% [7/15]; by adreno-oophorectomy, 61% [11/18]). Almost no breast cancers changed from ER- to Er+ during the endocrine therapy (by antiestrogen, 1/6; by adreno-oophorectomy, 0/10). All of six PgR+ tumors changed to PgR- after therapy. By chemotherapy treatment, 44% (4/9) ER+ cancers became ER-, while 19% (3/16) ER- tumors changed to ER+. After the simultaneous combination of chemotherapy and endocrine therapy, 67% (10/15) of ER+ cancers changed to ER-, and 20% (2/10) of ER- tumors changed to ER+. Through the intervention of more than two kinds of chemotherapy and/or endocrine therapy between the first treatment and the last therapy, 79% (19/24) ER+ breast cancers changed to ER-. Thus, ER and PgR contents of breast cancer gradually became negative as the malignancy progressed, and with some kinds of treatments particularly including endocrine therapy. The significance of changes in hormone receptors after therapy was discussed.
在癌症进展的几个阶段，作者检测了940例乳腺癌中的雌激素受体（ER）和773例癌症中的孕激素受体（PgR）。ER阳性和PgR阳性癌症的百分比随着恶性程度的进展而降低。对42例患者的原发性肿瘤和首次复发时的转移性肿瘤进行了ER和PgR的连续检测。在无病间期，27例ER阳性肿瘤中有10例（37%）变为ER阴性，所有15例ER阴性肿瘤仍为阴性。在治疗前以及肿瘤在消退后复发或癌症进展后对激素受体进行了检测。根据全身治疗的类型，研究了99例晚期乳腺癌患者ER和PgR的变化。通过内分泌治疗，观察到从ER阳性到ER阴性的显著变化（抗雌激素治疗，47%[7/15]；肾上腺-卵巢切除术，61%[11/18]）。在内分泌治疗期间，几乎没有乳腺癌从ER阴性变为ER阳性（抗雌激素治疗，1/6；肾上腺-卵巢切除术，0/10）。所有6例PgR阳性肿瘤治疗后均变为PgR阴性。通过化疗，44%（4/9）的ER阳性癌症变为ER阴性，而19%（3/16）的ER阴性肿瘤变为ER阳性。化疗和内分泌治疗同时进行后，67%（10/15）的ER阳性癌症变为ER阴性，20%（2/10）的ER阴性肿瘤变为ER阳性。在首次治疗和最后一次治疗之间通过两种以上化疗和/或内分泌治疗的干预，79%（19/24）的ER阳性乳腺癌变为ER阴性。因此，随着恶性程度的进展，尤其是在内分泌治疗等某些治疗方式下，乳腺癌的ER和PgR含量逐渐变为阴性。文中讨论了治疗后激素受体变化的意义。
